Published in Eur J Clin Microbiol Infect Dis on January 01, 2008
Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol (2009) 10.42
Distribution of genes encoding MSCRAMMs and Pili in clinical and natural populations of Enterococcus faecium. J Clin Microbiol (2009) 1.25
Prevalence and antimicrobial resistance pattern of methicillin resistant Staphylococcus aureus (MRSA) strains isolated from clinical specimens in Ardabil, Iran. Iran J Microbiol (2014) 1.21
In Vitro Antibacterial and Antibiotic Resistance Modifying Effect of Bioactive Plant Extracts on Methicillin-Resistant Staphylococcus epidermidis. Int J Microbiol (2013) 1.03
Exometabolome analysis identifies pyruvate dehydrogenase as a target for the antibiotic triphenylbismuthdichloride in multiresistant bacterial pathogens. J Biol Chem (2011) 0.93
Antimicrobial photodynamic therapy in the non-surgical treatment of aggressive periodontitis: microbiological profile. Lasers Med Sci (2011) 0.87
Bilateral sternoclavicular joint septic arthritis secondary to indwelling central venous catheter: a case report. J Med Case Rep (2008) 0.85
The treatment of diabetic foot infections: focus on ertapenem. Vasc Health Risk Manag (2009) 0.82
Efficacy of topically delivered moxifloxacin against wound infection by Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2011) 0.81
Mode of action of Van-M-02, a novel glycopeptide inhibitor of peptidoglycan synthesis, in vancomycin-resistant bacteria. Antimicrob Agents Chemother (2009) 0.79
In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species. Antimicrob Agents Chemother (2012) 0.76
In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides. Eur J Clin Microbiol Infect Dis (2010) 0.76
Characteristic of Enterococcus faecium clinical isolates with quinupristin/dalfopristin resistance in China. BMC Microbiol (2016) 0.75
Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe. Antimicrob Agents Chemother (2017) 0.75
Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens. Ther Adv Infect Dis (2017) 0.75
Staphylococcus aureus infections. N Engl J Med (1998) 36.39
Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev (2002) 17.58
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother (1997) 17.36
Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol (2002) 10.88
Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med (2006) 8.91
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med (2006) 8.20
Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med (1987) 7.82
Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med (2003) 7.52
Staphylococcus aureus resistant to vancomycin--United States, 2002. MMWR Morb Mortal Wkly Rep (2002) 7.34
Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis (2002) 5.94
Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 5.64
Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis (2004) 4.29
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis (2004) 4.06
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis (2004) 4.05
An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis (2003) 3.93
Coagulase-negative staphylococci: pathogens associated with medical progress. Clin Infect Dis (1994) 3.88
Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med (2003) 3.71
Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) (2003) 3.66
Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis (2002) 3.48
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother (2005) 3.34
Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother (2004) 2.76
Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol (2003) 2.74
Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother (2005) 2.66
Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis (2004) 2.48
Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis (2004) 2.46
Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm (2005) 2.34
The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med (2005) 2.33
Prevalence of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus aureus isolated from blood and nasal specimens. J Clin Microbiol (2003) 2.27
Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother (2005) 2.27
Vancomycin-resistant enterococci and use of avoparcin in animal feed: is there a link? Med J Aust (1999) 2.20
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis (2001) 2.19
Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother (2004) 2.17
Tigecycline. J Antimicrob Chemother (2005) 2.16
Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis (2003) 2.02
Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis (2006) 2.01
Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2003) 2.01
Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications. Emerg Infect Dis (1997) 1.96
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis (2005) 1.95
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother (2006) 1.84
MRSA--the tip of the iceberg. Clin Microbiol Infect (2006) 1.81
Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis (2003) 1.80
Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet (2003) 1.76
Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis (2004) 1.73
Alpha-toxin is required for biofilm formation by Staphylococcus aureus. J Bacteriol (2003) 1.73
Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet (2003) 1.70
Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med (1992) 1.69
In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother (2006) 1.68
Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? Clin Infect Dis (2005) 1.66
The glycylcyclines: a comparative review with the tetracyclines. Drugs (2004) 1.64
Tigecycline: what is it, and where should it be used? J Antimicrob Chemother (2005) 1.61
Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis (2003) 1.60
Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis (2004) 1.59
Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother (2005) 1.56
Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs (2004) 1.56
Mitochondrial toxicity associated with linezolid. N Engl J Med (2005) 1.52
Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy (2007) 1.52
Vancomycin-resistant enterococci. Am J Med (1997) 1.51
Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother (1994) 1.51
Comparison of in vitro activity of quinolone antibiotics and vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus by time-kill kinetic studies. Antimicrob Agents Chemother (1986) 1.40
The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother (1999) 1.39
The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med (2006) 1.39
Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother (2005) 1.37
In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother (2002) 1.32
Daptomycin: a new drug class for the treatment of Gram-positive infections. Drugs Today (Barc) (2005) 1.29
Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis (2005) 1.25
An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother (2002) 1.24
Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis (2003) 1.19
Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection (2004) 1.13
Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2003) 1.13
Daptomycin. Drugs (2004) 1.12
In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother (2003) 1.12
Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother (2000) 1.12
Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Antimicrob Agents Chemother (1996) 1.10
In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus. J Antimicrob Chemother (1997) 1.10
Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother (2004) 1.09
In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother (2003) 1.08
Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother (1998) 1.04
Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med (2000) 1.00
Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother (1999) 0.97
Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother (2006) 0.97
Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin (2005) 0.96
Recent developments in glycopeptide antibacterials. Curr Opin Investig Drugs (2005) 0.95
Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics. Antimicrob Agents Chemother (2001) 0.94
Daptomycin - a novel antibiotic against Gram-positive pathogens. Expert Opin Pharmacother (2004) 0.92
Daptomycin: a cyclic lipopeptide antimicrobial agent. Clin Ther (2004) 0.90
Linezolid-associated peripheral neuropathy. Mayo Clin Proc (2004) 0.89
Linezolid therapy for orthopedic infections. Mayo Clin Proc (2004) 0.88
Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother (2001) 0.88
Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother (2003) 0.88
Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections. J Clin Microbiol (2002) 0.87
Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin. Diagn Microbiol Infect Dis (2006) 0.87
Linezolid induced toxic optic neuropathy. Br J Ophthalmol (2005) 0.85
Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis (2003) 0.85
In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates. J Antimicrob Chemother (1998) 0.82
Risk factors for arthralgias or myalgias associated with quinupristin-dalfopristin therapy. Pharmacotherapy (2003) 0.82
Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance--a controlled study. Int J Antimicrob Agents (2007) 0.78
Hematologic effects of linezolid versus vancomycin. Clin Infect Dis (2004) 0.77
Linezolid for the treatment of a heteroresistant Staphylococcus aureus shunt infection. Pediatr Neurosurg (2005) 0.77
The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother (2005) 0.76
Vancomycin-resistant enterococci: causes and control. Med J Aust (1999) 0.75
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med (2001) 9.08
Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature (1999) 8.70
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med (1996) 6.49
Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med (1991) 5.85
Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med (1993) 4.72
Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis (2000) 4.24
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med (2000) 4.21
Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol (2001) 4.19
Legionellosis. N Engl J Med (1997) 4.12
New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) (1990) 4.04
Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med (1989) 3.98
Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia. Lancet (1993) 3.89
Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care (1996) 3.70
Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis (1993) 3.68
Ubiquitousness of Legionella pneumophila in the water supply of a hospital with endemic Legionnaires' disease. N Engl J Med (1982) 3.25
Serratia marcescens: historical perspective and clinical review. N Engl J Med (1979) 3.08
Methicillin-resistant staphylococcal colonization and infection in a long-term care facility. Ann Intern Med (1991) 3.04
Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int (2006) 3.00
Isolation of Legionella pneumophila from hospital shower heads. Ann Intern Med (1981) 2.89
Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Ann Intern Med (1981) 2.80
Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents (1999) 2.64
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis (1998) 2.61
Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol (2001) 2.52
Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med (1986) 2.44
Disease due to the Legionellaceae (other than Legionella pneumophila). Historical, microbiological, clinical, and epidemiological review. Medicine (Baltimore) (1989) 2.31
Evaluation of housestaff physicians' preparation and interpretation of sputum Gram stains for community-acquired pneumonia. J Gen Intern Med (1991) 2.28
Roseomonas, a new genus associated with bacteremia and other human infections. J Clin Microbiol (1993) 2.28
Infections caused by Pseudomonas maltophilia with emphasis on bacteremia: case reports and a review of the literature. Rev Infect Dis (1983) 2.27
Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy. AJR Am J Roentgenol (2000) 2.20
Diagnosis of Legionnaires' disease. An update of laboratory methods with new emphasis on isolation by culture. JAMA (1983) 2.14
Identification of a new variable sequence in the P1 cytadhesin gene of Mycoplasma pneumoniae: evidence for the generation of antigenic variation by DNA recombination between repetitive sequences. Infect Immun (1999) 2.11
Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med (1996) 2.09
Mode of transmission of Legionella pneumophila. A critical review. Arch Intern Med (1986) 2.04
Molecular cloning and pro-apoptotic activity of ICErelII and ICErelIII, members of the ICE/CED-3 family of cysteine proteases. J Biol Chem (1995) 2.02
Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis (2007) 1.87
Osteomyelitis due to Veillonella parvula: case report and review. Clin Infect Dis (1992) 1.86
Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination. Antimicrob Agents Chemother (1979) 1.86
Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis (2000) 1.83
Ecology of Legionella pneumophila within water distribution systems. Appl Environ Microbiol (1985) 1.83
Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study. Am J Med (1986) 1.81
Comparison of molecular methods for subtyping patients and epidemiologically linked environmental isolates of Legionella pneumophila. J Infect Dis (1988) 1.80
Epidemiologic perspectives on Enterobacter for the infection control professional. Am J Infect Control (1994) 1.78
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother (1995) 1.77
A pink-pigmented, oxidative, nonmotile bacterium as a cause of opportunistic infections. Arch Intern Med (1989) 1.73
Isolation and structure of the bacterial sex pheromone, cAD1, that induces plasmid transfer in Streptococcus faecalis. FEBS Lett (1984) 1.73
Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer (2003) 1.63
Comparative susceptibilities of Pseudomonas aeruginosa to 1-oxacephalosporin (LY 127935) and eight other antipseudomonal antimicrobial agents (old and new). Antimicrob Agents Chemother (1980) 1.62
A glomerular permeability factor produced by human T cell hybridomas. Kidney Int (1991) 1.61
Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med (1995) 1.59
High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med (1994) 1.59
Quantitative evaluation of vascular permeability in the gerbil brain after transient ischemia using Evans blue fluorescence. J Cereb Blood Flow Metab (1988) 1.59
Antimicrobial selection by a computer. A blinded evaluation by infectious diseases experts. JAMA (1979) 1.56
Manual of culture methodology for Legionella. Semin Respir Infect (1987) 1.54
Extended-spectrum beta-lactamases: a call for improved detection and control. Clin Infect Dis (1999) 1.53
Infections caused by Pseudomonas maltophilia. Expanding clinical spectrum. Arch Intern Med (1987) 1.53
Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis. Arch Otolaryngol Head Neck Surg (1989) 1.50
Beta-Lactam antibiotic-induced leukopenia in severe hepatic dysfunction: risk factors and implications for dosing in patients with liver disease. Am J Med (1993) 1.46
Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med (1992) 1.46
Listeria monocytogenes peritonitis in cirrhotic patients. Value of ascitic fluid gram stain and a review of literature. Dig Dis Sci (1994) 1.43
Potable water as a cause of sporadic cases of community-acquired legionnaires' disease. N Engl J Med (1992) 1.43
Role of aerobic gram-negative rods, anaerobes, and fungi in wound infection after head and neck surgery: implications for antibiotic prophylaxis. Head Neck (1989) 1.41
Protecting tomorrow's health care professionals against hepatitis B virus today. Arch Intern Med (1991) 1.40
Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994. Clin Infect Dis (1996) 1.38
Overproduction of antiplatelet antibody against glycoprotein IIb after splenectomy in a patient with Evans syndrome resulting in acquired thrombasthenia. Acta Haematol (1998) 1.38
Clinical demonstration of isolation of Nocardia asteroides on buffered charcoal-yeast extract media. J Clin Microbiol (1992) 1.36
Isolation of Pittsburgh pneumonia agent from nebulizers used in respiratory therapy. Ann Intern Med (1980) 1.36
Encephalitis and retarded growth of chicks caused by Sitiawan virus, a new isolate belonging to the genus Flavivirus. Am J Trop Med Hyg (2001) 1.35
Legionnaires' disease: new clinical perspective from a prospective pneumonia study. Am J Med (1982) 1.34
Nasal carriage of and infection with Staphylococcus aureus in HIV-infected patients. Ann Intern Med (1999) 1.32
Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology (1994) 1.32
In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother (1996) 1.29
MYCIN II: design and implementation of a therapy reference with complex content-based indexing. Proc AMIA Symp (1998) 1.28
Invasive gastrointestinal zygomycosis in a liver transplant recipient: case report and review of zygomycosis in solid-organ transplant recipients. Clin Infect Dis (1995) 1.28
Efficacy of two third-generation cephalosporins in prophylaxis for head and neck surgery. Arch Otolaryngol (1984) 1.25
Legionnaires' disease acquired within the homes of two patients. Link to the home water supply. JAMA (1987) 1.25
Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation (1997) 1.23
Potable water supply as the hospital reservoir for Pittsburgh pneumonia agent. Lancet (1982) 1.22
Comparative assessment of chlorine, heat, ozone, and UV light for killing Legionella pneumophila within a model plumbing system. Appl Environ Microbiol (1987) 1.22
Human acetyltransferase polymorphisms. Mutat Res (1997) 1.21
Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy. Am J Med (1988) 1.21
Prenatal and neonatal exposure to bisphenol-A enhances the central dopamine D1 receptor-mediated action in mice: enhancement of the methamphetamine-induced abuse state. Neuroscience (2003) 1.19
Growth of 28 Legionella species on selective culture media: a comparative study. J Clin Microbiol (1993) 1.19
Pneumonia due to the Pittsburgh pneumonia agent: new clinical perspective with a review of the literature. Medicine (Baltimore) (1983) 1.17
Central nervous system lesions in adult liver transplant recipients: clinical review with implications for management. Medicine (Baltimore) (1994) 1.17
Synergy assessed by checkerboard. A critical analysis. Diagn Microbiol Infect Dis (1993) 1.16
Measurement of serum and tissue concentration of moxalactam using high pressure liquid chromatography. Ther Drug Monit (1981) 1.16
Potential in-hospital modes of transmission of Legionella pneumophila. Demonstration experiments for dissemination by showers, humidifiers, and rinsing of ventilation bag apparatus. Am J Med (1986) 1.15
Apoptotic cytosol facilitates Bax translocation to mitochondria that involves cytosolic factor regulated by Bcl-2. Cancer Res (1999) 1.14
Cefamandole-susceptible strains of Legionella pneumophila serogroup 1: implications for diagnosis and utility as an epidemiological marker. J Clin Microbiol (1992) 1.14
Synergistic interaction in vitro with use of three antibiotics simultaneously against Pseudomonas maltophilia. J Infect Dis (1980) 1.14
Determinants of Legionella pneumophila contamination of water distribution systems: 15-hospital prospective study. Infect Control (1987) 1.14
Malignant external otitis: utility of CT in diagnosis and follow-up. Radiology (1990) 1.13
Staphylococcus aureus nasal carriage in hemodialysis patients. Its role in infection and approaches to prophylaxis. Arch Intern Med (1989) 1.13
A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res (1996) 1.13
Bacteremia in transplant recipients: a prospective study of demographics, etiologic agents, risk factors, and outcomes. Am J Infect Control (1992) 1.10
Can Legionnaires disease be diagnosed by clinical criteria? A critical review. Chest (2001) 1.10
Pseudomonas stutzeri bacteremia associated with hemodialysis. Arch Intern Med (1983) 1.10
Staphylococcus lugdunensis endocarditis--the hidden peril of coagulase-negative staphylococcus in blood cultures. Eur J Clin Microbiol Infect Dis (2003) 1.08
Determinants of nontraditional therapy use in patients with HIV infection. A prospective study. Arch Intern Med (1996) 1.08